MACE Risk with Coronary Calcium Score of Zero
A coronary artery calcium score of zero confers an exceptionally low risk of major adverse cardiovascular events, with annual event rates consistently below 1% and often as low as 0.5% per year, even in symptomatic patients. 1
Quantifying the Risk
The evidence demonstrates remarkably consistent findings across multiple populations:
- Asymptomatic patients: In a systematic review of 13 studies including 29,312 patients with CAC=0, only 0.47% experienced adverse cardiovascular events over 50 months of follow-up 1
- Annual mortality rate: Less than 1% yearly for over 15 years in a consecutive series of 9,715 asymptomatic patients 1
- Symptomatic stable chest pain: Annual MACE rate of 0.5% 2, with the most recent 2024 study showing only 0.5% MACE risk in symptomatic patients initially referred for invasive coronary angiography 3
- Acute chest pain: 0.8% overall event rate during follow-up 2
Clinical Implications by Risk Category
Borderline Risk Patients (5-10% 10-year ASCVD risk)
When CAC=0, the 10-year event rate drops to only 1.5%, compared to 7.4% in those with CAC>0 1. Statin therapy can be safely deferred in this group, particularly in the absence of active smoking or family history of premature CAD 1.
Intermediate Risk Patients (10-20% 10-year ASCVD risk)
The 10-year event rate remains low at 1.5-3.0% when CAC=0 1. Risk can be reclassified downward and statin treatment deferred, especially without high-risk features like active smoking, diabetes, chronic inflammatory conditions, or family history of premature CAD 1.
High Risk Patients
Even in patients classified as high risk (>20%) by Framingham risk score, mortality with CAC=0 remained <1% for the first 5 years 1. This demonstrates that CAC=0 is a stronger predictor than traditional risk scores alone.
The "Power of Zero" - Key Mechanistic Insights
The prognostic strength of CAC=0 stems from several factors:
- Negative predictive value: 97-98% for ruling out obstructive coronary artery disease 2
- Prevalence of obstructive CAD: Only 1.9-4.4% in CAC=0 patients undergoing CT angiography 3, 4, 5
- Risk reduction: Patients with CAC=0 have 92-94% lower MACE risk compared to those with CAC>0 (relative risk 0.06-0.08) 3, 6
Important Caveats and Limitations
Non-Calcified Plaque Risk
While rare, non-calcified plaque can exist in 8-9% of CAC=0 patients, with approximately 2% having ≥50% stenosis 5. In high cardiovascular risk populations with negative social determinants of health, discrete non-calcified plaque in CAC 0-100 patients was associated with a 5.7% adverse event rate 7. This emphasizes that CAC=0 does not guarantee complete absence of atherosclerosis.
Ethnic and Demographic Considerations
Recent evidence suggests that ethnic variations and symptomatic status may affect the predictive accuracy of CAC=0 8. Patients from certain ethnic backgrounds or those who are symptomatic may have confounding risk factors leading to higher-than-predicted risk even with CAC=0.
Duration of Protection
The "warranty period" of CAC=0 varies by patient characteristics 1:
- Low-risk patients: Repeat scanning in 5-7 years
- Borderline-to-intermediate risk: Repeat in 3-5 years
- High-risk or diabetic patients: Repeat in 3 years
- Patients with risk factors: Reconsider treatment decisions in 3-5 years
Treatment Recommendations for CAC=0
For most patients with CAC=0, statin therapy can be safely deferred 1. The number needed to treat (NNT) to prevent one ASCVD event over 10 years is 64 for CAC=0 patients, compared to only 28 for CAC>100 1.
However, aggressive lifestyle modification remains essential regardless of CAC score 1. The following warrant continued vigilance despite CAC=0:
- Active smoking
- Diabetes mellitus
- Family history of premature CAD
- Chronic inflammatory conditions
Practical Algorithm
For patients with CAC=0:
- Reassure about low short-term risk (annual MACE rate <1%)
- Defer statin therapy unless high-risk features present (active smoking, diabetes, strong family history)
- Emphasize lifestyle modification as primary intervention
- Schedule repeat CAC based on baseline risk (3-7 years depending on risk factors)
- Consider clinical context: In high-risk populations or symptomatic patients, maintain heightened awareness that rare non-calcified plaque may exist
The evidence consistently demonstrates that CAC=0 provides powerful risk stratification with very low MACE rates across diverse populations, making it an excellent tool for avoiding unnecessary treatment while identifying the small subset requiring intervention 9, 1, 3, 2.